Challenges and Gaps in the Management of Chronic Hepatitis C Infection: Insight from A Tertiary Hospital in Indonesia
), Cecilia Octaria Permatadewi(2), Hesti Triwahyu Hutami(3), Didik Indiarso(4), Hery Djagat Purnomo(5),
(1) Trainee of Gastroentero-Hepatology, Internal Medicine Department, Faculty of Medicine Diponegoro University, Kariadi Hospital, Semarang, Indonesia
(2) Division of Gastroentero-Hepatology, Internal Medicine Department, Faculty of Medicine Diponegoro University, Kariadi Hospital, Semarang Indonesia
(3) Division of Gastroentero-Hepatology, Internal Medicine Department, Faculty of Medicine Diponegoro University, Kariadi Hospital, Semarang Indonesia
(4) Division of Gastroentero-Hepatology, Internal Medicine Department, Faculty of Medicine Diponegoro University, Kariadi Hospital, Semarang Indonesia
(5) Division of Gastroentero-Hepatology, Internal Medicine Department, Faculty of Medicine Diponegoro University, Kariadi Hospital, Semarang Indonesia
Corresponding Author
Abstract
Background: Hepatitis C virus (HCV) infection remains a significant public health burden in Indonesia, affecting approximately 2.5 million people. The introduction of direct-acting antivirals (DAAs) has revolutionized HCV management by offering highly effective and well-tolerated treatment options. Since 2017, Indonesia has implemented an HCV cascade of care and a government-funded DAA program to support the World Health Organization (WHO) goal of HCV elimination by 2030. However, challenges in diagnostic accessibility and treatment follow-up continue to hamper progress. This study aims to evaluate the implementation of the HCV cascade of care at Dr. Kariadi General Hospital, Semarang, Indonesia.
Methods: A retrospective descriptive study was conducted at Dr. Kariadi General Hospital, which included data from patients who tested positive for anti-HCV antibodies between January 2019 and November 2024. HCV treatment was categorized into five stages: (1) positive anti-HCV antibody test, (2) HCV RNA test, (3) positive HCV RNA result, (4) treatment initiation, and (5) sustained virologic response 12 weeks post-treatment (SVR12). Data analysis was performed using SPSS Statistics version 26. Categorical variables were expressed as frequencies and percentages, and findings were presented as numbers and proportions across each stage of the care cascade.
Results: Among 317 patients with positive anti-HCV antibody results (55% men, 45% women; median age: 56 years), 280 (88%) underwent HCV RNA testing, and 213 (76%) were confirmed positive. Of these, 185 patients (87%) initiated treatment, 144 (78%) completed therapy, and 108 (75%) achieved SVR12.
Conclusion: This study shows that significant gaps remain at various stages of the HCV care cascade, particularly in confirmatory HCV RNA testing, treatment initiation, and post-treatment follow-up.
Keywords
References
World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018.
Trickey A, Hiebert L, Perfect C, Thomas C, El Kaim JL, Vickerman P, et al. Hepatitis C virus elimination in Indonesia: epidemiological, cost and cost-effectiveness modelling to advance advocacy and strategic planning. Liver Int. 2020;40:286–297.
World Health Organization. Hepatitis C [Internet]. Geneva: World Health Organization; 2023 [cited 2026 Mar 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–1218.
Jones AT, Briones C, Tran T, Moreno-Walton L, Kissinger PJ. Closing the hepatitis C treatment gap: United States strategies to improve retention in care. J Viral Hepat. 2022;29(8):588–595.
Scrutton J, Wallace J, Wait S. Situation analysis of viral hepatitis in Indonesia: a policy report. CEVHAV; 2018.
Indonesian Ministry of Health. Rencana aksi nasional pengendalian hepatitis 2020–2024. Jakarta: Ministry of Health Republic of Indonesia; 2020.
Boeke CE, Adesigbin C, Agwuocha C, Anartati A, Aung HT, Aung KS, et al. Initial success from a public health approach to hepatitis C testing, treatment, and cure in seven countries: the road to elimination. BMJ Glob Health. 2020;5:e003767.
Coalition for Global Hepatitis Elimination. Indonesia national hepatitis elimination profile [Internet]. 2023 [cited 2026 Mar 20]. Available from:
Gomes C, Ginzberg D, Wong RJ. Delays and gaps in progressing through the hepatitis C virus cascade of care: an underserved safety-net hospital experience. J Transl Intern Med. 2020;8(4):261–267.
Wei B, Ji F, Yeo YH, Ogawa E, Stave CD, Dang S, et al. Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia. BMJ Open Gastroenterol. 2018;5(1):e000239.
Huang C, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu Y, et al. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol Int. 2019;13(5):587–598.
Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019;71:660–665.
Niccum BA, Stine JG, Wynter JA, Kelly V, Caldwell SH, Shah NL. Success of direct-acting antiviral-based therapy for chronic hepatitis C is not affected by type 2 diabetes. Clin Diabetes. 2020;38(1):40–46.
Mangia A, Cenderello G, Copetti M, Verucchi G, Piazzolla V, Lorusso C, et al. SVR12 higher than 97% in GT3 cirrhotic patients with evidence of portal hypertension treated with SOF/VEL without ribavirin: A nation-wide cohort study. Cells. 2019;8(4):313.
Kuwano A, Yada M, Kurosaka K, Tanaka K, Masumoto A, Motomura K. Risk factors for loss to follow-up after the start of direct-acting antiviral treatment for hepatitis C virus infection. JGH Open. 2023;7:98–104.
Zarębska-Michaluk D, Brzdęk M, Tronina O, Janocha-Litwin J, Sitko M, Piekarska A, et al. Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination. BMC Med. 2024;22:468.
Heo M, Norton BL, Pericot-Valverde I, Mehta SH, Tsui JI, Taylor LE, et al. Optimal hepatitis C treatment adherence pattern and sustained virologic response among people who inject drugs: the HERO study. J Hepatol. 2024;80(5):702–713.
Cheng P, Mo L, Chen C, Chen C, Huang C, Kuo H, et al. Sofosbuvir/Velpatasvir for hepatitis C virus infection: real-world effectiveness and safety from a nationwide registry in Taiwan. Infect Dis Ther. 2021;11(1):485–500.
Article Metrics
Abstract View
: 84 times
Download : 44 times
DOI: 10.24871/271202645-50
Refbacks
- There are currently no refbacks.
